Saturday

25th Mar 2017

EU fines pharma-giants €427mn in ‘pay for delay’ case

  • French pharma-giant Servier was among a string of firms fined over €400 million in the EU's largest 'pay for delay' case. (Photo: Grumpy-Puddin)

French pharmaceutical firm Servier will bear the brunt of a €427 million anti-trust fine in the largest ‘pay for delay’ case brought by the European Commission.

Speaking at a news conference on Wednesday (9 July), EU competition commissioner Joaquin Almunia said Servier was guilty of protecting its bestselling blood pressure drug, perindopril, from price competition by generics in the EU between 2005 and 2007.

Dear EUobserver reader

Subscribe now for unrestricted access to EUobserver.

Sign up for 30 days' free trial, no obligation. Full subscription only 15 € / month or 150 € / year.

  1. Unlimited access on desktop and mobile
  2. All premium articles, analysis, commentary and investigations
  3. EUobserver archives

EUobserver is the only independent news media covering EU affairs in Brussels and all 28 member states.

♡ We value your support.

If you already have an account click here to login.

Perindopril generated more than $1 billion per year in sales for Servier, revenues which the company feared it would lose when its patent control over the drug’s molecule expired. Servier then bought the technology needed to develop an alternative version and made a series of patent settlements with companies trying to produce generic forms of the drug.

Servier now faces a €330 million fine, while Niche/Unichem, Matrix Teva, Krka and Lupin - all producers of generic medicines - face fines totalling €97 million.

Internal documents of one generic company acknowledged that it was being "bought out of perindopril," while another insisted that any settlement with Servier would have to be for a "pile of cash".

Describing the behaviour as a “serious breach” of the bloc’s competition rules, Almunia added that “’pay for delay’ is clearly not acceptable”.

For its part, Servier’s spokesperson Lucy Vincent described the ruling as “a bad sign” and indicated that the company plans to appeal. Servier had “acted in a transparent and legitimate way to defend its patents,” she said.

The case is the largest "pay for delay" case brought by the EU executive, where a company has paid off rival firms to prevent them producing cheaper generic versions of a drug.

Pharmaceutical firms use a variety of means including secondary patents and ‘pay for delay’ settlements to prevent rivals from producing generic version of their drugs at a fraction of the price.

But anti-trust regulators in the US and the EU are now investigating a series of similar cases.

Last November, the Commission fined Johnson & Johnson, Novartis, and Lundbeck for paying off their rivals in the EU’s first ‘pay for delay’ cases.

“A company tried hard to unduly prolong its exclusively … not thanks to its innovation and the strength of its patents but thanks to its deep pockets and the complicity of its rivals,” commented Almunia.

“Pharmaceuticals companies should focus their efforts on innovating rather than trying to extract extra rents for patients and taxpayers,” he added.

Opinion

Why are our medicines so expensive?

The EU should be promoting open innovation in upcoming trade talks with India and should work to bring down the prices of essential medicines, both abroad and within its borders.

Column / Brexit Briefing

The Union under threat

The effect of Brexit will be much more profound on Northern Ireland than on Scotland. Some kind of border controls with Ireland seem inevitable.

Bulgaria's election test

Sunday's general elections will be a test for the country's relations with the EU, Russia, and Turkey, as well as for the political future of former leader Borisov.

'Mr Putin steps into French elections'

Putin treated France's anti-EU firebrand, Le Pen, as if she had already won the elections. "I have my own viewpoint ... identical to Russia's", she said.

Stakeholders' Highlights

  1. European Gaming & Betting Association60 Years Rome Treaty – 60 Years Building an Internal Market
  2. Malta EU 2017New EU Rules to Prevent Terrorism and Give More Rights to Victims Approved
  3. European Jewish Congress"Extremists Still Have Ability and Motivation to Murder in Europe" Says EJC President
  4. European Gaming & Betting AssociationAudiovisual Media Services Directive to Exclude Minors from Gambling Ads
  5. ILGA-EuropeTime for a Reality Check on International Day for the Elimination of Racial Discrimination
  6. UNICEFHuman Cost to Refugee and Migrant Children Mounts Up One Year After EU-Turkey Deal
  7. Malta EU 2017Council Adopts New Rules to Improve Safety of Medical Devices
  8. Nordic Council of MinistersNordic Energy Research: How to Reach 100 Percent Renewable Energy
  9. Party of European SocialistsWe Must Renew Europe for All Europeans
  10. MEP Tomáš ZdechovskýThe European Commission Has Failed in Its Fight Against Food Waste
  11. ILGA-EuropeEP Recognises Discrimination Faced by Trans & Intersex People
  12. Nordic Council of Ministers25 Nordic Bioeconomy Cases for Sustainable Change